La Jolla, California · AI Therapeutics
Funding the Future of Medicine.
LJL Ventures is an early-stage fund backing AI-driven therapeutics companies that replace slow, expensive, traditional drug discovery with modern translational science: in silico models, organoid platforms, and AI tools that maximize efficiency from targets to human outcomes.
We believe AI is not a tool for drug discovery — it is the new foundation of medicine.
LJL Ventures invests at the intersection of artificial intelligence and therapeutic science. We partner with founders who are rebuilding the drug development stack from first principles — using machine learning, generative biology, and computational chemistry to compress timelines, reduce failure rates, and unlock targets that were previously undruggable.
Based in La Jolla, California — at the heart of one of the world's most concentrated biotech ecosystems — we bring deep scientific fluency and a global network of clinical, regulatory, and commercial partners.
Where We Invest
Three Layers of the AI Therapeutics Stack
Discovery Technology
AI-native platforms for target identification, molecular design, and hit-to-lead optimization across small molecules, biologics, and RNA therapeutics.
Development Technology
Computational tools and data infrastructure that accelerate IND-enabling studies, biomarker discovery, and clinical trial design.
Clinical Technology
Platforms that leverage real-world data, digital biomarkers, and adaptive trial design to improve the probability of regulatory success.
Our Edge
Why LJL Ventures
Scientific Depth
Our team includes PhD scientists and former drug developers who evaluate opportunities with the rigor of a research institution.
La Jolla Ecosystem
Embedded in one of the world's premier biotech clusters — with direct access to Scripps, Salk, UCSD, and a dense network of operators.
Full-Stack Perspective
We invest across the entire AI therapeutics stack — from discovery platforms to clinical-stage assets — and connect portfolio companies across layers.